Patents by Inventor Sebastian Barradeau

Sebastian Barradeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of PAK inhibitor for the treatment of a joint disease
    Patent number: 8187828
    Abstract: The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
    Type: Grant
    Filed: March 26, 2008
    Date of Patent: May 29, 2012
    Assignee: Sanofi-Aventis Deutschland GmnH
    Inventors: Sebastian Barradeau, Eckart Bartnik, Joerg Czech, Andreas R. Klatt, Ekkehard Leberer, Thomas Leeuw
  • USE OF PAK INHIBITOR FOR THE TREATMENT OF A JOINT DISEASE
    Publication number: 20090104279
    Abstract: The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
    Type: Application
    Filed: March 26, 2008
    Publication date: April 23, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sebastian BARRADEAU, Eckart BARTNIK, Joerg CZECH, Andreas R. Klatt, Ekkehard LEBERER, Thomas LEEUW
  • Use of PAK inhibitor for the treatment of a joint disease
    Patent number: 7364887
    Abstract: The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: April 29, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Sebastian Barradeau, Eckart Bartnik, Joerg Czech, Andreas R. Klatt, Ekkehard Leberer, Thomas Leeuw
  • Use of PAK inhibitor for the treatment of a joint disease
    Publication number: 20050037965
    Abstract: The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.
    Type: Application
    Filed: July 16, 2004
    Publication date: February 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Sebastian Barradeau, Eckart Bartnik, Joerg Czech, Andreas Klatt, Ekkehard Leberer, Thomas Leeuw